Myeloma: First-in-Class ADC Regimen Yields Key Benefits

The DREAMM-8 trial showed that adding belantamab mafodotin to pomalidomide and dexamethasone significantly improved progression-free survival in patients with relapsed or refractory multiple myeloma.
Medscape Medical News